A recently published study explores the possible benefits to discontinuing an alpha-1 blocker after receiving combination therapy with a 5-alpha reductase inhibitor for the treatment of benign prostatic hyperplasia (BPH). In more symptomatic patients, or patients with confirmed, enlarged prostates, it is recommended to use both medication classes (alpha-1 blocker and 5-alpha reductase inhibitor) to minimize symptoms by relaxing the prostatic smooth muscle and reducing the size of the prostate – producing a potentially synergistic effect. This study found that withdrawal of alpha 1-blockers after a year of combination therapy did not worsen urinary symptoms, QOL, and voiding or storage function. This provides evidence that combination therapy may not be needed indefinitely for all patients.
Guest Authors: Erica Crannage, PharmD and Stephanie Crist, PharmD
Music by Good Talk
Top Ten Things Every Clinician Should Know About Infographics
Mind Over Migraine: Can Mindfulness Improve Outcomes?
Is Home Blood Pressure Monitoring a “Home Run” for Blood Pressure Management?
Increasing the Patient-Clinician Connection: the “Presence 5 Practices”
FAST Take: Update on Febuxostat Cardiovascular Safety
Metformin During Pregnancy: Are the Results MiTy Enough to Change Practice?
Can a Polypill ‘TIP’ the Scale to a One-Size-Fits All Approach?
There’s an App for That! Can Smartphone Apps Assist with Smoking Cessation?
DECLARE-ing Another Victory for Dapagliflozin
Closing the Loop for Children with Type 1 Diabetes
Is it Time to Add Colchicine to the CVD Cocktail?
Canagliflozin Comeback? New Data on the Risk of Amputation
Using shared decision-making tools: Are they worth it?
Less Might Be Better: Deprescribing Antihypertensive Medications in Older Adults
Extracting Data on CBD: Effects on Opioid Use and Quality of Life
I Screen, You Screen, We Should All Screen for Unhealthy Drug Use
Implementing Comprehensive Medication Management – Ingredients for Success
Can VOYAGER Put PAD Patients Back on Their Feet?
Will Bempedoic Acid provide SERENITY for Patients with Statin Intolerance?
No Provider Status, No Problem: CCM as a Revenue Source in Community Pharmacy
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive